|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2200 - 0.3198|
|52 Week Range||0.1700 - 3.6400|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
The offer, revealed Monday in a filing in U.S. Bankruptcy Court in Wilmington, Del., is subject to higher bids at a court-supervised auction. The deal would include the world-wide rights to anti-obesity drug Contrave. to name the investor group’s acquisition vehicle, Nalpropion Pharmaceuticals Inc., as the stalking horse, or lead bidder, at the auction.
SAN DIEGO, April 23, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. to sell substantially all of the assets of the company, subject to court approval. Under the terms of the agreement, Orexigen will sell the world-wide rights to Contrave® (naltrexone HCl / bupropion HCl extended release) /Mysimba™ (naltrexone HCl and bupropion HCl prolonged release) and certain other Orexigen assets for $75 million in cash. The deal is subject to higher and better offers.
This is a summary of a request from Orexigen Therapeutics Inc. to hire Morris Nichols Arsht & Tunnell LLP as Delaware bankruptcy co-counsel, filed March 23 with the U.S. Bankruptcy Court in Wilmington, ...
Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGS in the over the last fewRead More...
The 30 most obese countries in the world in 2018 represent a huge (pun intended) market opportunity for weight loss drugmakers. Increasingly sedentary lifestyles and a lack of healthy eating habits among large swaths of the global population have resulted in dramatically rising obesity rates in the past few decades, particularly in urban settings. Obesity is […]
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Shares of Orexigen (OREX) have declined more than 75% of its value as the company announced that it is filing for bankruptcy.
A bankruptcy judge approved $35 million in new loans for drugmaker Orexigen Therapeutics, which said it would use some of the money to advertise its anti-obesity drug, Contrave.
Drugmaker Orexigen filed for bankruptcy protection on Monday and plans to sell itself, after failing to find a profitable market for its weight-loss treatment Contrave.
Biopharmaceutical company Orexigen Therapeutics plans to sell itself later this year through bankruptcy proceedings.
Drugmaker Orexigen Therapeutics Inc said on Monday it filed for Chapter 11 bankruptcy protection and will also file a motion to pursue an auction and sale process of substantially all its assets. The company, which focuses on the treatment of obesity, said it expects proposed bids to be submitted by May 21 and the sale is intended to be concluded by July 2. Orexigen listed assets in the range of $50 million to $100 million and liabilities in the range of $100 million to $500 million, according to a filing in the Delaware bankruptcy court.
SAN DIEGO, March 12, 2018 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX), a biopharmaceutical company focused on the treatment of obesity, announced today that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. Orexigen also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. The proposed bidding procedures, if approved by the court, would require interested parties to submit binding offers to acquire substantially all of Orexigen's assets, which would be purchased free and clear of the company's indebtedness and other liens and interests.
In this article, I’m going to take a look at Orexigen Therapeutics Inc’s (NASDAQ:OREX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Orexigen Therapeutics, Inc. Here are 5 ETFs with the largest exposure to OREX-US. Comparing the performance and risk of Orexigen Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Orexigen Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Orexigen Therapeutics, Inc. – Arena Pharmaceuticals, Inc., VIVUS, Inc., Zafgen, Inc. and Lannett Company, Inc. (ARNA-US, VVUS-US, ZFGN-US and LCI-US) that have also reported for this period. Highlights ... Read more (Read more...)
Investors in Orexigen Therapeutics (OREX) need to pay close attention to the stock based on moves in the options market lately.
Orexigen Therapeutics Inc (NASDAQ:OREX), a USD$27.89M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
Orexigen Therapeutics Inc (NASDAQ:OREX), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...
On a per-share basis, the La Jolla, California-based company said it had a loss of $1.35. The drug developer for obesity and weight loss posted revenue of $18.9 million in the period. In the final minutes ...
Orexigen reports Contrave total third quarter prescription volume in the United States grew 26% year-over-year SAN DIEGO , Nov. 13, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today ...